Mario Domenico Rizzato

List of Publications by Year
in descending order

31 papers	273 citations	933410 10 h-index	940516 16 g-index
33 all docs	33 docs citations	33 times ranked	441 citing authors

#	Article	IF	Citations
1	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. European Journal of Cancer, 2022, 166, 165-175.	2.8	17
2	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 370-379.	7.7	31
3	Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician's Choice: A Propensity Score-Matched Analysis. Targeted Oncology, 2021, 16, 401-410.	3.6	5
4	Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma: efficacy, safety and prognostic factors. Digestive and Liver Disease, 2021, 53, S10.	0.9	0
5	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3665-3671.	2.5	12
6	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	3.4	4
7	Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. JCO Precision Oncology, 2021, 5, 1166-1177.	3.0	55
8	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open, 2021, 6, 100190.	4.5	12
9	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	3.6	0
10	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	3.6	12
11	Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International, 2020, 1, 6-11.	1.3	0
12	405MO Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases. Annals of Oncology, 2020, 31, S413.	1.2	3
13	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	7.0	13
14	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	2.5	29
15	Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
16	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (United States), 2020, 99, e19958.	1.0	13
17	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
18	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0

#	Article	IF	Citations
19	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
20	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. , 2020, 15, e0232449.		0
21	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease, 2019, 51, 1713-1719.	0.9	18
22	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Annals of Oncology, 2019, 30, iv113.	1.2	0
23	OC.07.6 CAPECITABINE IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER EXPERIENCE. Digestive and Liver Disease, 2019, 51, e96.	0.9	0
24	Capecitabine in advanced hepatocellular carcinoma: a multicenter experience. Digestive and Liver Disease, 2019, 51, e40.	0.9	0
25	THU-448-Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. Journal of Hepatology, 2019, 70, e356.	3.7	0
26	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Gastrointestinal Tumors, 2019, 6, 71-80.	0.7	4
27	Advanced intrahepatic cholangiocarcinoma (iCCA) treated with arterial-directed therapies (ADT): Outcomes and safety from a multicenter Italian experience. Annals of Oncology, 2018, 29, viii261.	1.2	1
28	Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: TheÂTOREADOR Study. Clinical Colorectal Cancer, 2018, 17, e601-e615.	2.3	18
29	TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). Annals of Oncology, 2016, 27, iv43.	1.2	0
30	TRUST: Phase II trial of induction chemotherapy (CT) with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC). Annals of Oncology, 2016, 27, vi170.	1.2	1
31	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. Journal of Cancer Research and Clinical Oncology, 2016, 142, 679-685.	2.5	7